In this white paper, we will discuss the predominant formats and mechanisms of action of bispecific antibodies, the most common techniques for bsabs transient production, and what is involved in their process development Developers and their cdmo partners must thoroughly evaluate and optimize the immunogenicity of bispecific antibodies early in the developmental process to reduce risks and prioritize patient safety. Cell engagers, dual target blockers, dual immunomodulators, and cell surface protein bridges With 80+ bsab discovery projects and 14 ind clearances, probio provides a comprehensive hub for bsab resources—from discovery through gmp manufacturing. From cell line development and process optimization to conjugation chemistry and aseptic filling, the cdmo sector now plays a decisive role in global biologics innovation. Master bispecific antibody formulation challenges
Learn how to choose the right cdmo to ensure stability & accelerate drug development The integration of bispecific antibodies into community oncology practice offers promising therapeutic advancements but also presents substantial logistical, operational, and clinical challenges As these agents are relatively new in the treatment landscape for multiple myeloma (mm), many clinicians have limited familiarity with the associated adverse events (aes), and the evolving.
OPEN
